Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 10/20 | 0.59 |
| ▸ | LTA4H | P09960 | 5/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18713855 | 0.88 | FKBP1A (0.55) | FKBP1A | |
| SCHEMBL82714 | 0.80 | PREP (0.62) | FKBP1AALDH1A1SMN1; SMN2 | |
| SCHEMBL28450788 | 0.80 | FKBP1A (0.50) | FKBP1ALTA4HALDH1A1SMN1; SMN2ACE | |
| SCHEMBL28989843 | 0.80 | FKBP1A (0.50) | FKBP1ALTA4HALDH1A1SMN1; SMN2ACE | |
| SCHEMBL630208 | 0.80 | PREP (0.62) | FKBP1AALDH1A1SMN1; SMN2 | |
| SCHEMBL630241 | 0.80 | PREP (0.62) | FKBP1AALDH1A1SMN1; SMN2 | |
| SCHEMBL28450790 | 0.80 | FKBP1A (0.50) | FKBP1ALTA4HALDH1A1SMN1; SMN2ACE | |
| SCHEMBL7650461 | 0.79 | PREP (0.61) | FKBP1AALDH1A1SMN1; SMN2 | |
| SCHEMBL7648948 | 0.79 | PREP (0.61) | FKBP1AALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29077433 | 0.79 | PREP (0.61) | FKBP1AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505761-B2 | Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2016-11-29 | — | — | US | disclosed |
| US-9393239-B2 | Bicyclic compounds and their use as antibacterial agents and betalactamase inhibitors | FEDORA PHARMACEUTICALS INC. (CA) | 2016-07-19 | — | — | US | disclosed |
| US-8877743-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NAEJA PHARMACEUTICAL INC. (CA) | 2014-11-04 | — | — | US | disclosed |
| US-20140288051-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | FEDORA PHARMACEUTICALS INC. (CA) | 2014-09-25 | — | — | US | disclosed |
| US-8796257-B2 | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors | NAEJA PHARMACEUTICAL INC. (CA) | 2014-08-05 | — | — | US | disclosed |
| US-20130281359-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | FEDORA PHARMACEUTICALS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288051-A1 | BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | MGAM, PGLS, MRPL21 | FKBP1A 2626/4885LTA4H 896/4885ITGB3 4434/4885 |
| US-20130281359-A1 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS | MRPL21, MGAM, BACE1 | FKBP1A 3207/4885LTA4H 720/4885ITGB3 4436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.